RAPID KILLING OF CLOSTRIDIUM DIFFICILE
MGB Biopharma’s focus is to further develop their completely new class of anti-infective medicine, starting with antibiotics based on Minor Groove Binder (MGBs) compounds.
The Company’s experienced management team have dedicated their initial focus to the development of a new class of small molecules, with specific antibacterial activity against susceptible and resistant bacteria. In providing a new class of drug to the field of antibacterial resistance, based on a truly novel mechanism of action, MGB Biopharma are unique, in that a truly new class and novel MoA was last seen in the year 2000.
There are many drugs used to treat bacterial infections, and generally they belong to classes which have been in use for several decades. Due to the rise in resistant strains of bacteria, several of these drugs are becoming less and less effective.
The Company’s progress has been rapid, and our lead drug candidate, MGB-BP-3, has recently completed a Phase IIa clinical proof of concept study, in which efficacy of 100% was seen in the critical outcomes of initial and sustained cure. The results of the study demonstrate potential for superiority over the current standard of care, confirming that MGB-BP-3 offers a new paradigm in the treatment of Clostridium difficile-associated diarrhea (CDAD).
MGB-BP-3 is just the first in our new exciting class of anti-infectives.